2023年5月6日

證券訴訟合夥人詹姆斯•威爾遜(Josh)鼓勵投資者遭受損失超過100000美元在安進公司直接聯係他討論他們的選擇紐約,紐約——(Newsfile corp .) - 5月5日,2023)—Faruqi & Faruqi LLP領先國家證券法律公司正在調查潛在索賠安進,Inc .(“安進公司”或“公司”)(納斯達克:出現),提醒投資者的5月12日,2023年的最後期限,尋求導致原告的角色在一個聯邦證券集體訴訟,起訴這家公司。安進如果你遭受的損失超過100000美元投資於股票或期權在7月29日,2020年4月27日,2022年,想討論你的合法權益,直接調用Faruqi & Faruqi夥伴傑克威爾遜在877-247-4292或877-247-4292(分機1310)。你也可以點擊這裏獲取更多信息:www.faruqilaw.com/AMGN。沒有成本或義務。Faruqi & Faruqi是主要的少數民族和國家證券法律事務所Woman-owned在紐約設有辦事處,賓夕法尼亞州,加州和格魯吉亞。如下詳細,訴訟關注該公司及其高管是否違反了聯邦證券法律通過虛假或誤導性陳述和/或未能披露:(1)美國政府聲稱安進欠的稅款超過30億美元稅收2010年,2011年和2012年;(2)美國政府聲稱安進欠的稅款超過50億美元稅收2013年,2014年和2015年;(3)美國政府可能會聲稱安進欠美國政府物質超過投資者相信後續稅年安進公司使用了相同的利潤分配治療之間的美國和波多黎各操作;(4)安進公司沒有采取足夠的收益占其欠稅責任;(5)安進公司未能遵守ASC 450和其他規章製度有關的準備周期美國證券交易委員會的文件; and (6) Amgen's refusal to pay taxes claimed by the U.S. government exposed Amgen to a substantial risk of severe financial penalties imposed by the U.S. Internal Revenue Service ("IRS"). On August 3, 2021, Amgen issued an earnings release for its second fiscal quarter of 2021, which, for the first time, disclosed massive outstanding tax liabilities sought by the IRS. The release stated that Amgen had received a Notice of Deficiency from the IRS in July 2021 which sought $3.6 billion in back taxes, plus interest, for tax years 2010, 2011, and 2012. On this news, the price of Amgen common stock fell by more than 6%. Then, on April 27, 2022, Amgen issued an earnings release for its first fiscal quarter of 2022, which disclosed that Amgen had received a Notice of Deficiency from the IRS in April 2022 which sought $5.1 billion in back taxes, plus interest, for tax years 2013, 2014, and 2015, and proposed a $2 billion penalty as a result of Amgen's improper tax avoidance strategies. On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors. Amgen has additionally disclosed that it is under examination by the IRS for the years 2016 to 2018 for similar issues as the prior Notices of Deficiency for years 2010 to 2015, as well as examination by various state and foreign tax jurisdictions. Amgen has also admitted that "the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations." The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Amgen's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/164983 Sign up for Alerts Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies belonging to the Banking/Financial Services industry.